PACB Stock Declines Despite Promising HiFi Sequencing Findings
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Barclays Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
This Insider Has Just Sold Shares In Pacific Biosciences of California
Pacific Biosciences Of California To Present At J.P. Morgan Conference ; Webcast At 7:30 PM ET
Pacific Biosciences Shares Are Trading Lower After the Company Issued Worse-than-expected Preliminary Q4 Revenue.
Pacific Biosciences Total Preliminary Unrestricted Cash, Cash Equivalents, and Investments Balance as of Dec 31 Is Expected to Be $390M >PACB
Express News | Pacbio Announces Preliminary Fourth Quarter and Full Year Revenue
Press Release: PacBio Announces Preliminary Fourth Quarter and Full Year Revenue
Pacific Biosciences Sees FY24 Rev $154M >PACB
Express News | Pacific Biosciences of California Q4 Revenue USD 39.2 Million Vs. IBES Estimate USD 40.5 Million
PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics
PacBio Stock May Gain Following the Collaborated Launch of GutID
Insider Sale: See Remarks of $PACB (PACB) Sells 34,405 Shares
Bernstein Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
PacBio and Intus Bio Launch GutID: The First Comprehensive Human Gut Health Test Using Advanced Sequencing Technology
Express News | Pacbio and Intus Bio Collaborate for Launch of Gutid, First at-Home Microbiome Test Powered by Hifi Sequencing
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
Express News | PacBio Ships First Vega Systems To Berry Genomics For Clinical Assay Development In Asian Markets, With Plans For NMPA Regulatory Approval And Over 50 Additional Units Committed
PacBio Announces Shipment of Vega Systems to Berry Genomics to Support Its Clinical Assay Development for Asian Markets